We are live on ! Find out more
NAGE

Niagen Bioscience
NAGE

53 hedge funds and large institutions have $33.1M invested in Niagen Bioscience in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

134% more capital invested

Capital invested by funds: $14.2M → $33.1M (+$18.9M)

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

26% more funds holding

Funds holding: 42 → 53 (+11)

3.56% more ownership

Funds ownership: 6.85% → 10.41% (+3.6%)

Holders
53
Holders Change
+11
Holders Change %
+26.19%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
14
Reduced
8
Closed
9
Calls
$6.84M
Puts
–
Net Calls
+$6.84M
Net Calls Change
+$6.84M

Top Buyers

Rank Fund Capital Flow
1
IC
Iconiq Capital
California
+$9.22M
2
Millennium Management
Millennium Management
New York
+$1.11M
3
PM
Precept Management
Texas
+$1.08M
4
Barclays
Barclays
United Kingdom
+$441K
5
Renaissance Technologies
Renaissance Technologies
New York
+$244K

Top Sellers

Rank Fund Capital Flow
1
NSIM
North Star Investment Management
Illinois
-$464K
2
VF
Virtu Financial
New York
-$272K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$156K
4
PHS
Pekin Hardy Strauss
Illinois
-$150K
5
ECM
Element Capital Management
New York
-$139K
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
26
Monashee Investment Management
Massachusetts
$140K – – –
Deutsche Bank
27
Deutsche Bank
Germany
$134K +$124K +22,874 +31,769%
AGM
28
Alpine Global Management
New York
$122K +$112K +20,680 New
GP
29
GLG Partners
United Kingdom
$97K +$89K +16,473 New
CS
30
Credit Suisse
Switzerland
$97K +$89.2K +16,518 New
Morgan Stanley
31
Morgan Stanley
New York
$96K +$76.7K +14,200 +676%
Goldman Sachs
32
Goldman Sachs
New York
$88K +$80.8K +14,966 New
CPIG
33
Chicago Partners Investment Group
Illinois
$88K +$81K +15,000 New
LPL Financial
34
LPL Financial
California
$70K +$63.9K +11,834 New
Ameriprise
35
Ameriprise
Minnesota
$68K +$62.4K +11,552 New
Creative Planning
36
Creative Planning
Kansas
$64K -$48.6K -9,000 -45%
MCM
37
MAI Capital Management
Ohio
$63K – – –
DWM
38
Dynasty Wealth Management
Florida
$61K +$55.6K +10,300 New
Bank of America
39
Bank of America
North Carolina
$28K – – –
OIA
40
OneDigital Investment Advisors
Kansas
$24K – – –
PCA
41
Peddock Capital Advisors
Massachusetts
$20K – – –
IP
42
Intellectus Partners
California
$12K +$10.8K +2,000 New
IWM
43
IHT Wealth Management
Illinois
$10K – – –
TC
44
Telemus Capital
Michigan
$10K +$9.18K +1,700 New
ASN
45
Advisory Services Network
Georgia
$9K – – –
HS
46
Horan Securities
United States
$8K +$864 +160 +15%
Carson Wealth (CWM LLC)
47
Carson Wealth (CWM LLC)
Nebraska
$6K +$5.4K +1,000 New
CG
48
Cutler Group
California
$5K +$4.86K +900 New
RE
49
RBC Europe
United Kingdom
$4.53K +$3.26K +604 +364%
AA
50
AlphaMark Advisors
Kentucky
$4K – – –
1
2
3

NAGE Hedge Fund Activity: Q4 2017 in Review

53 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2017, worth a combined $33.1M — up 134% from $14.2M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new NAGE positions and 9 closed out — a net gain of 11 holders — while 14 added to existing stakes and 8 trimmed.

The largest buyer was Iconiq Capital, opening a new position worth an estimated $9.22M. The largest seller was North Star Investment Management, cutting an estimated $464K.

  • 53 institutional investors held Niagen Bioscience (NAGE) as of Q4 2017, up from 42 in Q3 2017.
  • Funds reported $33.1M of Niagen Bioscience stock for Q4 2017, up 134% quarter-over-quarter.
  • 20 funds opened new Niagen Bioscience positions in Q4 2017 and 9 closed out, a net change of +11 holders.
  • The largest Niagen Bioscience buyer in Q4 2017 was Iconiq Capital, an estimated $9.22M added.
  • The largest Niagen Bioscience seller in Q4 2017 was North Star Investment Management, an estimated $464K sold.

Based on aggregated 13F filings for Q4 2017.